Australia markets closed
  • ALL ORDS

    7,599.60
    +36.50 (+0.48%)
     
  • AUD/USD

    0.7253
    +0.0020 (+0.28%)
     
  • ASX 200

    7,302.00
    +28.20 (+0.39%)
     
  • OIL

    70.51
    -0.05 (-0.07%)
     
  • GOLD

    1,779.50
    +1.30 (+0.07%)
     
  • BTC-AUD

    58,007.78
    -1,196.43 (-2.02%)
     
  • CMC Crypto 200

    1,041.62
    -22.23 (-2.09%)
     

Silo Pharma To Appear On National Media Broadcast on Psychedelics

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media tour on Thursday, July 22 from 8 a.m. – 11:30 a.m. EST.

The company has sponsored Radio Media LLC to facilitate the interviews to increase awareness of the potential benefits of psychedelic medicines. These benefits may include a wide range of conditions like mental illness, depression, chronic pain, rare neurological conditions, and inflammation.

The radio media tour will broadcast on stations across the United States and will include both nationally and regionally-focused programs. Listeners are expected to hear the radio broadcast on business and health program stations nationwide.

Dr. Josh Woolley, MD, PHD, the Director of the Translational Psychedelic Research (TrPR) Program and a Scientific Advisor Board Member of Silo Pharma will be participating in the program. Dr. Woolley will discuss psychedelic therapy research and studies that may be beneficial in treating various diseases.

Replay recordings and highlights from select interviews will be available shortly after on Silo Pharma’s web site, www.silopharma.com.

About Silo Pharma

Silo Pharma is a development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.

About Radio Media

Radio Media is a customer-focused media relations services company whose mission is to help you deliver your message effectively and work with you as a long-term media partner. Radio Media offers direct access to an expansive network of broadcast stations and national programs throughout North America as well as unmatched expertise in helping craft an effective strategy for building awareness. For more information, visit www.radiomedia.com.

Safe Harbor and Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR

Brett Maas
646-536-7331
Email: brett@haydenir.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting